Pfizer Inc. (NYSE:PFE) Given Consensus Rating of “Hold” by Analysts

Pfizer Inc. (NYSE:PFE) has been given an average recommendation of “Hold” by the twenty brokerages that are presently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, thirteen have issued a hold recommendation, four have issued a buy recommendation and two have given a strong buy recommendation to the company. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $27.8824.

Several research firms recently commented on PFE. HSBC reissued a “buy” rating and set a $29.00 price objective on shares of Pfizer in a report on Wednesday, December 10th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Pfizer in a research note on Wednesday, October 8th. Wolfe Research set a $24.00 target price on shares of Pfizer and gave the stock an “underperform” rating in a report on Wednesday, December 17th. BMO Capital Markets reissued an “outperform” rating on shares of Pfizer in a report on Wednesday, December 10th. Finally, UBS Group started coverage on shares of Pfizer in a report on Tuesday, January 6th. They issued a “neutral” rating and a $25.00 price target on the stock.

Pfizer Stock Down 0.8%

Shares of NYSE:PFE opened at $25.28 on Tuesday. The company has a market capitalization of $143.71 billion, a price-to-earnings ratio of 14.69 and a beta of 0.47. The business’s 50-day moving average is $25.28 and its 200-day moving average is $24.97. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.28 and a quick ratio of 0.97. Pfizer has a 1 year low of $20.92 and a 1 year high of $27.69.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, November 4th. The biopharmaceutical company reported $0.87 EPS for the quarter, beating analysts’ consensus estimates of $0.79 by $0.08. The firm had revenue of $16.65 billion during the quarter, compared to analysts’ expectations of $16.94 billion. Pfizer had a return on equity of 20.17% and a net margin of 15.65%.Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. Equities research analysts predict that Pfizer will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, March 6th. Investors of record on Friday, January 23rd will be paid a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 6.8%. The ex-dividend date of this dividend is Friday, January 23rd. Pfizer’s dividend payout ratio (DPR) is currently 100.00%.

Institutional Trading of Pfizer

Several hedge funds and other institutional investors have recently bought and sold shares of PFE. SeaCrest Wealth Management LLC boosted its position in Pfizer by 5.8% during the fourth quarter. SeaCrest Wealth Management LLC now owns 68,181 shares of the biopharmaceutical company’s stock valued at $1,724,000 after buying an additional 3,753 shares during the period. Benin Management CORP grew its position in Pfizer by 5.8% during the 4th quarter. Benin Management CORP now owns 24,524 shares of the biopharmaceutical company’s stock worth $611,000 after acquiring an additional 1,340 shares during the last quarter. Castleview Partners LLC increased its stake in Pfizer by 20.8% in the 4th quarter. Castleview Partners LLC now owns 13,495 shares of the biopharmaceutical company’s stock worth $336,000 after purchasing an additional 2,322 shares during the period. First Merchants Corp lifted its position in Pfizer by 14.6% in the fourth quarter. First Merchants Corp now owns 21,017 shares of the biopharmaceutical company’s stock valued at $523,000 after purchasing an additional 2,684 shares during the last quarter. Finally, LVM Capital Management Ltd. MI boosted its stake in shares of Pfizer by 1.0% during the fourth quarter. LVM Capital Management Ltd. MI now owns 328,276 shares of the biopharmaceutical company’s stock valued at $8,174,000 after purchasing an additional 3,356 shares during the period. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Key Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: CEO Albert Bourla says Pfizer expects a consumer-sized obesity market comparable to the post‑Viagra boom — signals management is prioritizing obesity as a multi‑year growth engine. Pfizer CEO plans for soaring consumer market for obesity drugs akin to Viagra
• Positive Sentiment: Pfizer completed a ~$10B Metsera acquisition and plans a big push on obesity drug development in 2026 — strategic M&A to accelerate pipeline and commercial scale in GLP‑1/obesity space. Pfizer CEO eyes big push towards obesity drug development in 2026 after $10B Metsera acquisition
• Positive Sentiment: New trial data: Pfizer’s cancer combo showed stronger tumor shrinkage versus standard care in advanced colorectal cancer — supports oncology franchise growth and potential label/market share gains. Pfizer Cancer Combo Drug Shows Strong Tumor Shrinkage in Colorectal Cancer Trial
• Positive Sentiment: Pfizer advanced a global Phase 2/3 lung cancer combo and launched a Phase 3 head‑to‑head colorectal study (PF‑08634404) — meaningful pipeline catalysts if readouts are positive. Pfizer Advances New Lung Cancer Combo in Global Phase 2/3 Trial Pfizer’s New Colorectal Cancer Trial Puts PF-08634404 Head-to-Head With a Market Standard
• Positive Sentiment: Positive new data on the Braftovi regimen adds to oncology momentum and incremental revenue potential. Positive new data on Pfizer’s Braftovi regimen
• Neutral Sentiment: Pfizer presented at the J.P. Morgan Healthcare Conference (transcript available) — useful for detail but no single headline catalyst. Pfizer Inc. Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
• Neutral Sentiment: Coverage of partnerships with data/AI vendors (Tempus) and sector ETFs highlights industry tailwinds — supportive macro backdrop but not an immediate stock mover. Tempus AI (TEM) Stock: Why Big Pharma Is Betting Big on This AI Platform This ETF Is Proof That the Healthcare Rebound Is Real
• Negative Sentiment: UBS initiated coverage with a Neutral rating and $25 target, citing lingering revenue uncertainty tied to major drugs (~$15–20B exposure) — a near‑term cap on upside and reason for investor caution. UBS Likes Pfizer’s MTSR Obesity Deal but Stays Neutral on PFE

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.